clinical trial · NCT04661150
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Gastric CancerGastroesophageal Junction AdenocarcinomaAtezolizumabTrastuzumabCapecitabineOxaliplatin
brief summary
This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.
started
Mar 12, 2021
primary completion
May 8, 2023
completion
Jul 30, 2026
last updated
Jul 15, 2026
official title
A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) and Trastuzumab in Combination With Capecitabine and Oxaliplatin (Xelox) in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (GEJ)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol